Agur T, Steinmetz T, Goldman S, Zingerman B, Bielopolski D, Nesher E
Cardiovasc Diabetol. 2025; 24(1):97.
PMID: 40022102
PMC: 11871758.
DOI: 10.1186/s12933-025-02643-6.
Dousdampanis P, Aggeletopoulou I, Mouzaki A
Front Immunol. 2025; 15:1534823.
PMID: 39867890
PMC: 11758166.
DOI: 10.3389/fimmu.2024.1534823.
Eltahir H, Shalkami A, Shehata A, Almikhlafi M, Aldhafiri A, Alalawi A
Life (Basel). 2025; 14(12.
PMID: 39768376
PMC: 11676428.
DOI: 10.3390/life14121669.
Vukovic A, Karanovic D, Mihailovic-Stanojevic N, Miloradovic Z, Brkic P, Zivotic M
Biomedicines. 2025; 12(12.
PMID: 39767695
PMC: 11673868.
DOI: 10.3390/biomedicines12122788.
Delrue C, Eisenga M, Delanghe J, Speeckaert M
J Pers Med. 2024; 14(12).
PMID: 39728054
PMC: 11678888.
DOI: 10.3390/jpm14121141.
The pro-fibrotic role of autophagy in renal intrinsic cells: mechanisms and therapeutic potential in chronic kidney disease.
Zhang Y, Zhou X, Huang G, Liao W, Chen X, Ma Y
Front Cell Dev Biol. 2024; 12:1499457.
PMID: 39723243
PMC: 11669005.
DOI: 10.3389/fcell.2024.1499457.
Lebanese cannabis oil extract protected against folic acid-induced kidney fibrosis in rats.
Bylan D, Khalil A, Shebaby W, Habchy C, Nasser S, Faour W
PLoS One. 2024; 19(12):e0311790.
PMID: 39666622
PMC: 11637346.
DOI: 10.1371/journal.pone.0311790.
Development of a spontaneous model of renal interstitial fibrosis in NOD/SCID mice: Aging-induced pathogenesis.
Qiu L, Ma Z, Li J, Wu Z, Dai L, Long R
PLoS One. 2024; 19(12):e0315437.
PMID: 39661589
PMC: 11633998.
DOI: 10.1371/journal.pone.0315437.
Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts.
Rudman-Melnick V, Vanhoutte D, Stowers K, Sargent M, Adam M, Ma Q
Sci Rep. 2024; 14(1):29307.
PMID: 39592775
PMC: 11599588.
DOI: 10.1038/s41598-024-80930-0.
A PDE1 inhibitor, vinpocetine, ameliorates epithelial-mesenchymal transition and renal fibrosis in adenine-induced chronic kidney injury in rats by targeting the DNMT1/Klotho/β-catenin/Snail 1 and MMP-7 pathways.
Abdelfattah A, Mohammed Z, Talaat A, Samy W, Eldesoqui M, Elgarhi R
Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39276250
DOI: 10.1007/s00210-024-03393-0.
Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.
Perez-Villalobos M, Barba-Gonzalez A, Garcia-Carrillo N, Munoz-Ortega M, Sanchez-Aleman E, Avila-Blanco M
Exp Ther Med. 2024; 28(4):392.
PMID: 39161617
PMC: 11332140.
DOI: 10.3892/etm.2024.12681.
Long noncoding RNA MALAT1 as a ceRNA drives mouse fibroblast activation via the miR-335-3p/P2ry2 axis.
Chen M, Peng J, Zhu G, Qian C, Xiao Z, Song X
PLoS One. 2024; 19(8):e0308723.
PMID: 39133718
PMC: 11318857.
DOI: 10.1371/journal.pone.0308723.
Icariin suppresses nephrotic syndrome by inhibiting pyroptosis and epithelial-to-mesenchymal transition.
Duan S, Ding Z, Liu C, Wang X, Dai E
PLoS One. 2024; 19(7):e0298353.
PMID: 38995910
PMC: 11244770.
DOI: 10.1371/journal.pone.0298353.
Chlorogenic acid alleviates renal fibrosis by reducing lipid accumulation in diabetic kidney disease through suppressing the Notch1 and Stat3 signaling pathway.
Yang X, Jiang D, Wang Y, Duan M, Huang Y, Wang X
Ren Fail. 2024; 46(2):2371988.
PMID: 38952291
PMC: 11221469.
DOI: 10.1080/0886022X.2024.2371988.
Sorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3/MLKL pathway.
Abou Taha M, Ali F, Saleh I, Akool E
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):8961-8977.
PMID: 38874805
PMC: 11522075.
DOI: 10.1007/s00210-024-03146-z.
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.
Massoud G, Parish M, Hazimeh D, Moukarzel P, Singh B, Cayton Vaught K
Int Immunopharmacol. 2024; 137:112423.
PMID: 38861914
PMC: 11245748.
DOI: 10.1016/j.intimp.2024.112423.
MicroRNA-10 Family Promotes Renal Fibrosis through the VASH-1/Smad3 Pathway.
Shuai Y, Xu N, Zhao C, Yang F, Ning Z, Li G
Int J Mol Sci. 2024; 25(10).
PMID: 38791272
PMC: 11120755.
DOI: 10.3390/ijms25105232.
Emodin improves renal fibrosis in chronic kidney disease by regulating mitochondrial homeostasis through the mediation of peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α).
Feng L, Lin Z, Tang Z, Zhu L, Xu S, Tan X
Eur J Histochem. 2024; 68(2).
PMID: 38742403
PMC: 11128849.
DOI: 10.4081/ejh.2024.3917.
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis.
Hu J, Teng J, Hui S, Liang L
Heliyon. 2024; 10(8):e29486.
PMID: 38644817
PMC: 11031788.
DOI: 10.1016/j.heliyon.2024.e29486.
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.
Reiss A, Jacob B, Zubair A, Srivastava A, Johnson M, Leon J
J Clin Med. 2024; 13(7).
PMID: 38610646
PMC: 11012936.
DOI: 10.3390/jcm13071881.